Vancomycin for surgical prophylaxis?

Area of Science:

• Infectious Diseases
• Surgical Infection Prevention
• Antimicrobial Stewardship

Background:

• Increasing prevalence of methicillin-resistant Staphylococcus aureus (MRSA) necessitates reevaluating antibiotic prophylaxis protocols.
• Previous studies suggest cephalosporins are effective, but are outdated and do not reflect current MRSA rates.
• Current MRSA prevalence impacts the efficacy and cost-effectiveness of vancomycin for surgical site infection (SSI) prevention.

Purpose of the Study:

• To review the current evidence on vancomycin's role in surgical prophylaxis.
• To assess the effectiveness of vancomycin in high-MRSA prevalence settings.
• To determine optimal strategies for preventing SSIs caused by resistant pathogens.

Main Methods:

• Systematic reviews of randomized controlled trials.
• Time-series analyses in high-MRSA prevalence institutions.
• Decision analysis models to estimate MRSA prevalence thresholds.
• Review of combination therapy and resistance emergence.

Main Results:

• Existing evidence on cephalosporins vs. vancomycin is largely based on older data.
• Recent analyses evaluate vancomycin effectiveness in contemporary high-MRSA environments.
• Decision models identify specific MRSA prevalence rates where vancomycin might be beneficial.
• Emergence of resistant pathogens is a concern with vancomycin prophylaxis.

Conclusions:

• Vancomycin is not recommended for routine surgical prophylaxis.
• Consider vancomycin as part of a bundled approach for MRSA SSI prevention in select cases.
• Antimicrobial stewardship is crucial for managing resistance and optimizing SSI prevention strategies.